Silymarin in NAFLD
Launched by UNIVERSITY HOSPITAL RIJEKA · Nov 21, 2016
Trial Information
Current as of May 23, 2025
Withdrawn
Keywords
ClinConnect Summary
In this study will participate patients who come to the regular ambulatory examinations (referred by gastroenterologists, nephrologists or family physicians in the Department of Gastroenterology and Department of Nephrology, dialysis and kidney transplantation KBC Rijeka) and have one or more components of the metabolic syndrome (hypertension, diabetes, obesity, dyslipidemia).Nonalcoholic fatty liver disease will be defined by transient elastography (FibroScan, Echosens, Paris); Controlled Attenuation Parameter (CAP) for assesment of liver steatosis and Liver Stiffness Measurements (LSM) fo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • NAFLD patients
- • signed informed consent
- • possibility to follow instruction and the protocol
- Exclusion Criteria:
- • chronic B or C hepatitis
- • usage of hepatotoxic drugs in the period of 6 months before inclusion
- • chronic kidney insufficiency (grade 4 and 5), hemodialysis
- • any other chronic liver disease
- • opioid dependancy
- • any malignancy
- • HIV seropositivity
- • alcohol abuse
- • pregnancy
- • inability to follow the protocol
About University Hospital Rijeka
University Hospital Rijeka is a leading healthcare institution in Croatia, dedicated to advancing medical research and patient care. With a commitment to scientific innovation and clinical excellence, the hospital serves as a prominent sponsor of clinical trials, facilitating the development of new therapies and treatments across various medical disciplines. The institution leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous research, ensuring adherence to ethical standards and regulatory compliance. Through collaboration with academic partners and industry stakeholders, University Hospital Rijeka aims to enhance health outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rijeka, Kresimirova 42, Croatia
Patients applied
Trial Officials
Goran Hauser, MD, PhD
Principal Investigator
Clinical Hospital Centre Rijek, Croatia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials